DNA RNA and Cells

13 Nov 2020 Atara Biotherapeutics Presents New Preclinical Data on ATA3271, a Next-Generation Allogeneic Mesothelin-Targeted CAR T to Treat Solid Tumors, at the 35th Society for Immunotherapy of Cancer Annual Meeting (SITC 2020)
13 Nov 2020 CG Oncology Announces First Patient Dosed in Phase 1b Study of Oncolytic Immunotherapy CG0070 in Combination with OPDIVO® (nivolumab) in Muscle-Invasive Bladder Cancer
12 Nov 2020 Vor Biopharma Announces Exclusive License of Clinical-Stage CD33 CAR-T from National Cancer Institute
12 Nov 2020 UCB strengthens its gene therapy activities with additional pipeline programs, capabilities and platforms
12 Nov 2020 Cardior Pharmaceuticals Announces Positive Phase Ib Results of its Lead Compound CDR132L in Heart Failure
11 Nov 2020 Bioheng Announced Oral Presentation of Its Preliminary Results of CRISPR-Engineered Allogeneic CAR-T for r/r B-ALL Treatment at 2020 ASH Meeting
11 Nov 2020 Gyroscope Therapeutics Announces First Patient Dosed in Phase II HORIZON Trial Evaluating Investigational Gene Therapy, GT005, in People with Dry Age-Related Macular Degeneration
10 Nov 2020 Immatics Presents Phase I Data from ACTolog® Multi-Target Pilot Study IMA101 at the 35th Annual SITC Conference
10 Nov 2020 American Gene Technologies Announces First Trial Participant Enrolled in Phase 1 Study of AGT103-T Against HIV
10 Nov 2020 Locus Biosciences signs contract with CARB-X to advance $14 million precision medicine program to develop crPhage™ product targeting Klebsiella pneumoniae infections
10 Nov 2020 Medigene's MAGE-A4-specific TCR-Ts detect and fight cancer cells independent of CD8 co-receptor
09 Nov 2020 Axovant Gene Therapies Announces FDA Clearance of IND for AXO-AAV-GM2 Gene Therapy in Tay-Sachs and Sandhoff Diseases
09 Nov 2020 Repertoire Immune Medicines Presents First Clinical Data on PRIME IL-15 Cell Therapy in Advanced Metastatic Cancers at Society for Immunotherapy of Cancer (SITC) Annual Meeting
09 Nov 2020 OncoMyx Announces Presentation of Preclinical Efficacy Data of Novel Oncolytic Immunotherapy at SITC 2020
09 Nov 2020 Exicure Presents Positive Clinical Data with Cavrotolimod at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting
09 Nov 2020 Intellia Therapeutics Doses First Patient in Landmark CRISPR/Cas9 Clinical Trial of NTLA-2001 for the Treatment of Transthyretin Amyloidosis
09 Nov 2020 BioInvent and Transgene present data on next generation oncolytic virus BT-001 at the SITC 35[th] Anniversary Annual Meeting
09 Nov 2020 4D Pharma presents new data from two MRx0518 clinical trials at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
06 Nov 2020 Homology Medicines Announces Presentation of Positive Data from the Dose-Escalation Phase of the pheNIX Gene Therapy Trial for Adults with PKU
06 Nov 2020 Seres Therapeutics Announces Initiation of Phase 1b Trial of SER-301 for the Treatment of Ulcerative Colitis
05 Nov 2020 Allogene Therapeutics Announces Oral Presentation of Initial Results from its Phase 1 Dose Escalation Study of ALLO-715 in Relapsed/Refractory Multiple Myeloma at the 62nd Annual Meeting of the American Society of Hematology
05 Nov 2020 American Society of Hematology (ASH) Abstract Shows Initial Anti-Leukemic Activity of UCART22 in BALLI-01 Phase 1 Study in R/R Adult B-ALL
05 Nov 2020 Synlogic Initiates Phase 1 Study of SYNB8802 for the Treatment of Enteric Hyperoxaluria
05 Nov 2020 PharmaCyte Biotech Receives U.S. FDA Clinical Hold Letter
04 Nov 2020 BiomX Announces Dosing of First Subject in Phase 1a Study of BX002 Phage Therapy for Inflammatory Bowel Disease

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top